# Importance of Gut Microbiota in Patients with Inflammatory Bowel Disease

## TL;DR

This study explores how gut microbiota influences inflammatory bowel disease and how dysbiosis may contribute to its development.

## Contribution

The paper reviews high-level evidence on gut microbiota differences in IBD patients and potential therapeutic strains.

## Key findings

- IBD patients show significant intestinal dysbiosis compared to healthy individuals.
- Toll-like receptors in IBD patients misidentify gut bacteria as pathogens, triggering inflammation.
- Certain microbial strains may hold therapeutic potential for IBD treatment.

## Abstract

Inflammatory bowel diseases (IBDs), such as Crohn’s disease (CD) and ulcerative colitis (UC), are chronic diseases of the digestive system with a multifactorial and not fully understood etiology. There is research suggesting that they may be initiated by genetic, immunological, and lifestyle factors. In turn, all of these factors play an important role in the modulation of intestinal microflora, and a significant proportion of IBD patients struggle with intestinal dysbiosis, which leads to the conclusion that intestinal microflora disorders may significantly increase the risk of developing IBD. Additionally, in IBD patients, Toll-like receptors (TLRs) produced by intestinal epithelial cells and dendritic cells treat intestinal bacterial antigens as pathogens, which causes a disruption of the immune response, resulting in the development of an inflammatory process. This may result in the occurrence of intestinal dysbiosis, which IBD patients are significantly vulnerable to. In this study, we reviewed scientific studies (in particular, systematic reviews with meta-analyses, being studies with the highest level of evidence) regarding the microflora of patients with IBD vs. the microflora in healthy people, and the use of various strains in IBD therapy.